Cathie Wood’s ARK sells SpaceX stock, buys Nurix Therapeutics
ARK ETFs sold $49.2M in SpaceX shares, bought $9M in Nurix Therapeutics. Also sold Alphabet and Eli Lilly, bought Twist Bioscience and Pacific Biosciences. Transactions reflect ARK's strategic shifts in tech and biotech sectors.
How this was made
The 30-second read
Why it matters
Fund activity provides insight into sector rotation and may influence short-term price movements for the affected stocks.
Market read
The disclosed trades offer actionable signals for traders focusing on biotech and tech equities.
What to watch
Fund may be rebalancing for tax or liquidity reasons, not pure conviction.
Background
ARK Investment Management disclosed its daily ETF trades, showing portfolio rebalancing between tech and biotech.
Ticker impact
ARK purchased 350,410 shares of Nurix Therapeutics, indicating new bullish exposure.
likely upward pressure as fund buying is priced in
Fund inflow signals confidence and may attract other investors.
ARK sold 46,164 shares of Alphabet, reducing its stake.
likely modest pressure as a large fund reduces exposure
Sell may be interpreted as reduced confidence, but size is modest.
ARK sold 8,551 shares of Eli Lilly, trimming its pharma exposure.
likely slight pressure from fund sell
Sell size is small relative to market cap.
ARK bought 12,943 shares of Twist Bioscience, adding exposure to synthetic biology.
likely upward pressure as fund adds position
Buy indicates interest in niche biotech sector.
ARK increased holdings in Pacific Biosciences with 73,281 shares.
likely upward pressure as fund accumulates shares
Accumulation suggests confidence in company's growth prospects.
ARK sold 38,302 shares of Personalis, reducing its position.
likely slight pressure from fund sell
Sell size is modest; market may not react strongly.
ARK bought 25,758 shares of GeneDx Holdings, adding exposure to genetic testing.
likely upward pressure as fund adds position
Buy signals confidence in sector growth.
Market effects
ARK's shift toward biotech may boost sector sentiment.
US biotech and tech sectors see modest reallocation.
Limited to US-listed equities; no broader macro impact.
Counterpoint
ARK's reduction in large-cap tech could be a temporary tactical move, not a bearish signal.
Key entities
- PersonCathie Wood
Founder of ARK Invest, leading the fund's investment decisions.
- FundARK ETFs
Series of actively managed exchange-traded funds.
